Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Inhibrx Company

INBX
US45720L1070
A2PQMH

Price

15.27
Today +/-
+0.46
Today %
+3.40 %
P

Inhibrx stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Inhibrx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Inhibrx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Inhibrx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Inhibrx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Inhibrx Stock Price History

DateInhibrx Price
10/7/202415.27 undefined
10/4/202414.76 undefined
10/3/202414.88 undefined
10/2/202415.40 undefined
10/1/202415.45 undefined
9/30/202415.66 undefined
9/27/202415.52 undefined
9/26/202415.33 undefined
9/25/202415.42 undefined
9/24/202415.50 undefined
9/23/202415.67 undefined
9/20/202416.28 undefined
9/19/202417.49 undefined
9/18/202416.99 undefined
9/17/202417.22 undefined
9/16/202417.43 undefined
9/13/202416.41 undefined
9/12/202415.08 undefined
9/11/202415.00 undefined
9/10/202415.18 undefined
9/9/202415.20 undefined

Inhibrx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Inhibrx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Inhibrx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Inhibrx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Inhibrx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Inhibrx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Inhibrx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Inhibrx’s growth potential.

Inhibrx Revenue, EBIT and net profit per share

DateInhibrx RevenueInhibrx EBITInhibrx Net Income
2029e510.16 M undefined0 undefined13.14 M undefined
2028e353.69 M undefined-74.45 M undefined-18.17 M undefined
2027e344.61 M undefined-21.33 M undefined-7.24 M undefined
2026e124.4 M undefined-198.09 M undefined-74.44 M undefined
2025e0 undefined-240.98 M undefined-162.89 M undefined
2024e102,000 undefined-246.82 M undefined1.51 B undefined
20231.8 M undefined-219.22 M undefined-241.36 M undefined
20222.19 M undefined-129.12 M undefined-145.23 M undefined
20217.23 M undefined-76.56 M undefined-81.77 M undefined
202012.89 M undefined-67.44 M undefined-76.12 M undefined
201913.21 M undefined-40.95 M undefined-51.4 M undefined
20188.6 M undefined-29.51 M undefined-31.16 M undefined
20178.39 M undefined-19.73 M undefined-19.44 M undefined

Inhibrx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
88131272100124344353510
--62.50-7.69-41.67-71.43-50.00---177.422.6244.48
-------------
0000000000000
-19-29-40-67-76-129-219-246-240-198-21-740
-237.50-362.50-307.69-558.33-1,085.71-6,450.00-21,900.00---159.68-6.10-20.96-
-0.02-0.03-0.05-0.08-0.08-0.15-0.241.51-0.16-0.07-0.01-0.020.01
-63.1664.5249.026.5879.0166.21-725.31-110.75-54.32-90.54157.14-172.22
35.6536.6636.6637.7138.0140.1147.13000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Inhibrx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Inhibrx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
13.52.111.5128.7131.3273.9277.92
100700200100400200778
60002005005001000
0000000
1.32.93.62.96.96.416.66
15.55.715.5132.2139.1280.6295.36
1.82.610.711.39.57.29.37
0000000
0000000
0000000
0000000
01.70.20.21.83.23.16
1.84.310.911.511.310.412.54
17.31026.4143.7150.4291307.89
             
21.147.559.50000.01
000220.8279.5430.4657.23
-28.8-57.6-93.6-145.4-227.1-372.4-613.73
0000000
0000000
-7.7-10.1-34.175.452.45843.5
0.86.53.113.59.18.310.95
2.61.65.914.911.319.145.36
0.42.183.120.20
0000000
5.25.93.60000
916.120.631.522.427.656.31
9.53.630.429.270.5202.1206.97
0000000
0.20.49.67.65.13.21.11
9.744036.875.6205.3208.08
18.720.160.668.398232.9264.39
111026.5143.7150.4290.9307.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Inhibrx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Inhibrx's financial health and stability.

Assets

Inhibrx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Inhibrx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Inhibrx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Inhibrx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-22-31-51-76-81-145-241
001,0001,0001,0001,0001,000
0000000
14312-17315
351819324556
100031326
0000000
-18-23-32-47-80-115-193
-1-1-1-100-4
-1-1-1-100-4
0000000
0000000
-5-53341391280
20201213644130202
13134316683258201
-1.00-1.00-2.00-11.00---
0000000
-6-11911721424
-20.09-24.52-33.89-49.33-81.18-115.99-197.9
0000000

Inhibrx stock margins

The Inhibrx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inhibrx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inhibrx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Inhibrx's sales revenue. A higher gross margin percentage indicates that the Inhibrx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Inhibrx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Inhibrx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Inhibrx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Inhibrx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Inhibrx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Inhibrx Margin History

Inhibrx Gross marginInhibrx Profit marginInhibrx EBIT marginInhibrx Profit margin
2029e0 %0 %2.58 %
2028e0 %-21.05 %-5.14 %
2027e0 %-6.19 %-2.1 %
2026e0 %-159.23 %-59.84 %
2025e0 %0 %0 %
2024e0 %-241,977 %1.48 M %
20230 %-12,178.94 %-13,408.95 %
20220 %-5,895.89 %-6,631.51 %
20210 %-1,058.92 %-1,130.98 %
20200 %-523.2 %-590.54 %
20190 %-309.99 %-389.1 %
20180 %-343.14 %-362.33 %
20170 %-235.16 %-231.7 %

Inhibrx Stock Sales Revenue, EBIT, Earnings per Share

The Inhibrx earnings per share therefore indicates how much revenue Inhibrx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inhibrx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inhibrx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inhibrx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inhibrx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Inhibrx Revenue, EBIT and net profit per share

DateInhibrx Sales per ShareInhibrx EBIT per shareInhibrx Earnings per Share
2029e35.23 undefined0 undefined0.91 undefined
2028e24.43 undefined0 undefined-1.25 undefined
2027e23.8 undefined0 undefined-0.5 undefined
2026e8.59 undefined0 undefined-5.14 undefined
2025e0 undefined0 undefined-11.25 undefined
2024e0.01 undefined0 undefined104.08 undefined
20230.04 undefined-4.65 undefined-5.12 undefined
20220.05 undefined-3.22 undefined-3.62 undefined
20210.19 undefined-2.01 undefined-2.15 undefined
20200.34 undefined-1.79 undefined-2.02 undefined
20190.36 undefined-1.12 undefined-1.4 undefined
20180.23 undefined-0.8 undefined-0.85 undefined
20170.24 undefined-0.55 undefined-0.55 undefined

Inhibrx business model

Inhibrx Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies. The company was founded in 2011 and is headquartered in La Jolla, California. Inhibrx's business model is based on the research and development of innovative antibodies targeting various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. The company utilizes proprietary technologies and platforms to produce a wide range of antibodies that specifically target and block key proteins in the body. Inhibrx is divided into two business segments: the clinical development department and the research and development department. The clinical development department is responsible for conducting clinical trials of the company's antibodies. The research and development department is responsible for the development and refinement of new antibody platforms and technologies. Inhibrx has a number of products in the pipeline, including IRX-2, an antibody developed for the treatment of patients with solid tumor diseases. IRX-2 targets the PD-L1 and PD-L2 proteins, which are overexpressed by many cancer cells and help tumor cells evade immune defenses. In clinical studies, IRX-2 has shown significant reduction in tumor volume in many patients. Another promising product from Inhibrx is IRX-6, an antibody developed for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. IRX-6 targets the protein BAFF, which plays a key role in the activation of immune cells. Inhibrx has also partnered with pharmaceutical company Celgene Corporation to develop new cancer therapies. As part of the partnership, Inhibrx will utilize its proprietary antibody platforms and technologies to identify and develop new cancer therapies. Inhibrx has an excellent reputation in the industry and has been recognized multiple times for its innovative approaches and technologies. The company has secured a place among the leading biopharmaceutical companies and is expected to continue playing a significant role in the development of new therapies. Inhibrx is one of the most popular companies on Eulerpool.com.

Inhibrx Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Inhibrx Revenue by Segment

Segmente2023202220212020
License fee revenue1.8 M USD2.18 M USD7.13 M USD12.81 M USD
Grant revenue-14,000 USD106,000 USD80,000 USD
License fee revenue, non-affiliates--7.13 M USD10.81 M USD
License fee revenue1.8 M USD2.18 M USD--
License fee revenue, affiliates---2 M USD

Inhibrx SWOT Analysis

Strengths

Inhibrx Inc possesses several strengths that contribute to its success:

  • Strong research and development capabilities, enabling the company to innovate and develop new products.
  • Robust intellectual property portfolio, providing a competitive advantage in the industry.
  • Experienced and skilled team of scientists and researchers.
  • Strong financial position, allowing for investment in research and expansion.

Weaknesses

Despite its strengths, Inhibrx Inc also faces certain weaknesses:

  • Relatively small size in comparison to some competitors, limiting resources and reach.
  • Dependence on a limited number of key clients, potentially affecting revenue stability.
  • Long development and approval timelines for new products, leading to delays in market entry.

Opportunities

Inhibrx Inc can capitalize on several opportunities in the market:

  • Increasing demand for biopharmaceuticals, driven by aging populations and rising healthcare needs.
  • Emerging markets with expanding healthcare infrastructure, providing new markets for expansion.
  • Advancements in technology, such as gene editing and protein engineering, creating opportunities for new product development.

Threats

Inhibrx Inc faces certain threats that may impact its business:

  • Intense competition from larger pharmaceutical companies with greater resources and established market presence.
  • Regulatory hurdles and strict compliance requirements, which can delay product approvals and increase costs.
  • Uncertainty surrounding healthcare policies and reimbursement systems, affecting pricing and market access.

Inhibrx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Inhibrx historical P/E ratio, EBIT multiple, and P/S ratio

Inhibrx shares outstanding

The number of shares was Inhibrx in 2023 — This indicates how many shares 47.13 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Inhibrx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Inhibrx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Inhibrx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Inhibrx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Inhibrx.

Inhibrx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-3.67 125.48  (3,517.21 %)2024 Q2
3/31/2024-1.06 -1.44  (-35.75 %)2024 Q1
12/31/2023-1.06 -1.73  (-63.61 %)2023 Q4
9/30/2023-1.03 -1.1  (-6.78 %)2023 Q3
6/30/2023-1.05 -1.08  (-2.5 %)2023 Q2
3/31/2023-0.86 -1.12  (-30.1 %)2023 Q1
12/31/2022-0.8 -0.95  (-18.19 %)2022 Q4
9/30/2022-0.96 -0.9  (6.23 %)2022 Q3
6/30/2022-0.79 -0.97  (-22.15 %)2022 Q2
3/31/2022-0.61 -0.8  (-30.87 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Inhibrx stock

Eulerpool World ESG Rating (EESG©)

26/ 100

🌱 Environment

5

👫 Social

31

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Inhibrx shareholders

%
Name
Stocks
Change
Date
7.47393 % Loomis, Sayles & Company, L.P.1,082,225-34,25912/31/2023
6.60829 % ArrowMark Colorado Holdings, LLC956,881-9,11512/31/2023
5.33810 % Sofinnova Investments, Inc772,95729,66312/31/2023
49.38416 % Viking Global Investors LP7,150,826012/31/2023
4.91961 % Capital Research Global Investors712,360-509,36112/31/2023
4.78577 % BofA Global Research (US)692,980577,23112/31/2023
4.74696 % Geode Capital Management, L.L.C.687,36041,20112/31/2023
4.13161 % Forsyth Douglas598,25702/21/2024
32.62574 % RA Capital Management, LP4,724,207012/31/2023
3.71522 % PFM Health Sciences, LP537,964249,34712/31/2023
1
2
3
4
5
...
10

Inhibrx Executives and Management Board

Mr. Mark Lappe56
Inhibrx Chairman of the Board of Director, President, Chief Executive Officer, Co-Founder (since 2010)
Compensation 1.02 M
Ms. Kelly Deck43
Inhibrx Chief Financial Officer
Compensation 1.02 M
Dr. Brendan Eckelman44
Inhibrx Co-Founder, Chief Scientific Officer (since 2010)
Compensation 704,000
Mr. Douglas Forsyth54
Inhibrx Independent Director
Compensation 200,950
Dr. Jon Kayyem59
Inhibrx Independent Director
Compensation 190,450
1
2

Inhibrx Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
2seventy Bio Stock
2seventy Bio
SupplierCustomer-0,030,810,670,94--
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,26-0,50-0,60-0,85-0,87-
1

Most common questions regarding Inhibrx

What values and corporate philosophy does Inhibrx represent?

Inhibrx Inc represents a commitment to precision medicine and drug discovery. The company is guided by a corporate philosophy centered around scientific excellence and delivering innovative therapies to patients in need. Inhibrx Inc focuses on the development of biologics that target critical pathways involved in various diseases, including cancer and autoimmune disorders. With a strong emphasis on research and collaboration, Inhibrx Inc strives to advance the field of therapeutic antibodies and contribute to improved patient outcomes. As a result, Inhibrx Inc is positioned as a leading player in the biopharmaceutical industry, driving advancements in precision medicine for a better future.

In which countries and regions is Inhibrx primarily present?

Inhibrx Inc is primarily present in the United States.

What significant milestones has the company Inhibrx achieved?

Inhibrx Inc, a renowned biotechnology company, has achieved several significant milestones. The company successfully developed and advanced its proprietary therapeutic candidates for various serious diseases. Inhibrx Inc reached key partnerships and collaborations, expanding its global reach and maximizing its potential. Their dedication to scientific innovation and commitment to developing cutting-edge treatments have garnered notable attention and recognition within the industry. Inhibrx Inc's breakthrough achievements highlight their continuous efforts in advancing patient care and improving outcomes.

What is the history and background of the company Inhibrx?

Inhibrx Inc is a biotechnology company that was founded in 2010. It specializes in the discovery and development of therapeutic antibodies for the treatment of various diseases. The company is headquartered in La Jolla, California and has a strong research and development focus. Inhibrx has a robust portfolio of proprietary biologic candidates that target a range of diseases, including cancer and autoimmune disorders. With a dedicated team of experts and a promising pipeline, Inhibrx Inc is committed to advancing innovative antibody therapeutics to improve patient outcomes.

Who are the main competitors of Inhibrx in the market?

The main competitors of Inhibrx Inc in the market include renowned pharmaceutical companies such as Amgen, Inc., Pfizer Inc., Merck & Co., Inc., and Novartis AG.

In which industries is Inhibrx primarily active?

Inhibrx Inc is primarily active in the biopharmaceutical industry.

What is the business model of Inhibrx?

The business model of Inhibrx Inc revolves around developing and commercializing innovative therapeutics. Inhibrx focuses on creating differentiated protein therapeutics that can address unmet medical needs. The company utilizes its proprietary cell-free protein expression system to design and manufacture therapeutics with precise targeting capabilities. By leveraging its expertise in protein engineering, Inhibrx aims to develop therapies for various indications, including oncology, rare diseases, and inflammation. Through strategic collaborations and partnerships, Inhibrx strives to bring its novel therapeutics to patients and provide potential advancements in healthcare.

What is the P/E ratio of Inhibrx 2024?

The Inhibrx P/E ratio is 0.48.

What is the P/S ratio of Inhibrx 2024?

The Inhibrx P/S ratio is 7,055.64.

What is the Quality Investing of Inhibrx?

The Quality Investing for Inhibrx is 3/10.

What is the revenue of Inhibrx 2024?

The expected Inhibrx revenue is 102,000 USD.

How high is the profit of Inhibrx 2024?

The expected Inhibrx profit is 1.51 B USD.

What is the business model of Inhibrx

Inhibrx Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutics for serious diseases. The company takes a holistic approach from discovery to clinical development of innovative therapy options for cancer, inflammatory diseases, chronic pain syndromes, and other serious diseases. Please note that the translation provided above may not be an exact translation, as languages have different structural and linguistic conventions.

What is the Inhibrx dividend?

Inhibrx pays a dividend of 0 USD distributed over payouts per year.

How often does Inhibrx pay dividends?

The dividend cannot currently be calculated for Inhibrx or the company does not pay out a dividend.

What is the Inhibrx ISIN?

The ISIN of Inhibrx is US45720L1070.

What is the Inhibrx WKN?

The WKN of Inhibrx is A2PQMH.

What is the Inhibrx ticker?

The ticker of Inhibrx is INBX.

How much dividend does Inhibrx pay?

Over the past 12 months, Inhibrx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibrx is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibrx?

The current dividend yield of Inhibrx is .

When does Inhibrx pay dividends?

Inhibrx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibrx?

Inhibrx paid dividends every year for the past 0 years.

What is the dividend of Inhibrx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibrx located?

Inhibrx is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibrx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibrx from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.

When did Inhibrx pay the last dividend?

The last dividend was paid out on 10/8/2024.

What was the dividend of Inhibrx in the year 2023?

In the year 2023, Inhibrx distributed 0 USD as dividends.

In which currency does Inhibrx pay out the dividend?

The dividends of Inhibrx are distributed in USD.

All fundamentals about Inhibrx

Our stock analysis for Inhibrx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibrx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.